Evidence map›Paper›PMID 22164189›Full record

ArticleTherapeutic advances in neurological disorders2011

Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America.

Adriana Carrá, Miguel Ángel Macías-Islas, Alberto Alan Gabbai, Jorge Correale, Carlos Bolaña, Eduardo Duriez Sotelo, Juan García Bonitto, Fernando Vergara-Edwards, Darwin Vizcarra-Escobar

Abstract read
In one paragraph

Article in Therapeutic advances in neurological disorders, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Observational
  5. Observational
  6. Article
  7. Application of the McDonald criteria in Latin America.Multiple sclerosis journal - experimental, translational and clinical
    Review
  8. Multiple sclerosis in Colombia: A review of the literature.Multiple sclerosis journal - experimental, translational and clinical
    Review
  9. Access and barriers to MS care in Latin America.Multiple sclerosis journal - experimental, translational and clinical
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adriana Carrá
Miguel Ángel Macías-Islas
Alberto Alan Gabbai
Jorge Correale
Carlos Bolaña
Eduardo Duriez Sotelo
Juan García Bonitto
Fernando Vergara-Edwards
Darwin Vizcarra-Escobar

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe prevalence of multiple sclerosis (MS) in Latin America varies across different studies but an intermediate risk and increased frequency of the disease have been reported in recent years. The circumstances of Latin American countries are different from those of Europe and North America, both in terms of differential diagnoses and disease management.

methodsAn online survey on MS was sent to 855 neurologists in nine Latin American countries. A panel of nine experts in MS analyzed the results.

resultsDiagnostic and therapeutic recommendations were outlined with special emphasis on the specific needs and circumstances of Latin America. The experts proposed guidelines for MS diagnosis, treatment, and follow up, highlighting the importance of considering endemic infectious diseases in the differential diagnoses of MS, the identification of patients at high risk of developing MS in order to maximize therapeutic opportunities, early treatment initiation, and cost-effective control of treatment efficacy, as well as global assessment of disability.

conclusionsThe experts recommended that healthcare systems allocate a longer consultation time for patients with MS, which must be conducted by neurologists trained in the management of the disease. All drugs currently approved must be available in all Latin American countries and must be covered by healthcare plans. The expert panel supported the creation of a permanent forum to discuss future clinical and therapeutic recommendations that may be useful in Latin American countries.

Indexed as

glatiramer acetateimmunomodulatorsinterferon-betamitoxantronemultiple sclerosisnatalizumab

Identifiers

PMID22164189
PMCPMC3229255

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.